A Novel Bioactive Peptide, T14, Selectively Activates mTORC1 Signalling: Therapeutic Implications for...

Area of Science:

• Neuroscience
• Molecular Biology
• Cellular Biology

Background:

• T14 modulates calcium influx via the α-7 nicotinic acetylcholine receptor, impacting cell growth.
• Dysregulation of this pathway is linked to Alzheimer's disease (AD) and cancer.
• Mammalian target of rapamycin complex 1 (mTORC1) is crucial for cell growth but hyperactivated in AD and cancer.

Purpose of the Study:

• To investigate the role of T30 (a precursor to T14) in mTORC1 activation.
• To determine if T14 selectively targets mTORC1 or mTORC2.
• To assess the therapeutic potential of selective T14 blockade.

Main Methods:

• T30-induced mTORC1 and mTORC2 activation was measured in PC12 cells and rat brain slices.
• The effect of NBP14 (T14 blocker) on T30-induced mTORC1 activation was evaluated.
• T14 and mTORC1 levels were correlated in post-mortem human midbrain samples.
• mTORC1 and mTORC2 silencing were used to assess their role in T30-mediated effects.

Main Results:

• T30 increased mTORC1, but not mTORC2, in PC12 cells and rat substantia nigra.
• NBP14 attenuated T30-induced mTORC1 increase in PC12 cells.
• T14 levels positively correlated with mTORC1 in human midbrain.
• Silencing mTORC1, but not mTORC2, reversed T30's effects on PC12 cells.

Conclusions:

• T14 selectively activates mTORC1, suggesting a specific mechanism in cell growth regulation.
• T14 blockade represents a promising therapeutic strategy for AD and cancer by selectively targeting mTORC1.
• Selective mTORC1 blockade via T14 inhibition may mitigate side effects associated with general mTOR inhibitors.